Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Core Insights - Vigil Neuroscience Inc. has released data from its completed Phase 1 trial for VG-3927, a potential treatment for Alzheimer's disease [1] Group 1: Clinical Trial Results - The Phase 1 clinical trial demonstrated a robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid (CSF) [6] - The company plans to advance a once-daily oral dose of 25mg and expects to initiate the Phase 2 trial in Q3 2025 [3] - The trial showed consistent target engagement across participant groups, with cohort means showing reductions in sTREM2 ranging from 20% to 25% in the highest three dose levels [3][4] Group 2: Safety and Tolerability - The trial demonstrated a favorable safety and tolerability profile across all cohorts, including the elderly cohort, with all adverse events being mild or moderate and self-resolving [6] - No serious adverse events were reported during the trial [6] Group 3: Market and Valuation - Vigil's market capitalization is lower than the cash reported at the end of Q3 last year, indicating the company is significantly undervalued compared to its potential [4] - Analyst Sarah Schram views the trial results as encouraging preliminary support for target engagement, maintaining an Outperform rating for the stock [3][4] - Following the news, VIGL stock increased by 21.40%, reaching $2.47 [4]